Establishing efficacy of a new experimental treatment in the 'gold standard' design

Biometrical Journal

Volumn 47, Issue 6, 2005, Pages 782-786

  Hauschke, Dieter ^a   Pigeot, Iris ^b  

^a ALTANA PHARMA AG   (Germany)

^b LEIBNIZ INSTITUTE FOR PREVENTION RESEARCH AND EPIDEMIOLOGY BIPS   (Germany)

Author keywords

Assay Sensitivity; Fieller's Confidence Interval; Gold Standard Design; Proof of Efficacy; Relative Efficacy

Indexed keywords

ASSAY SENSITIVITY; CLINICAL TRIAL; CONFIDENCE INTERVAL; ETHICAL CONCERNS; FIELLE CONFIDENCE INTERVAL; GOLD STANDARD DESIGN; GOLD STANDARDS; PROOF OF EFFICACY; RELATIVE EFFICACY; STANDARD DESIGN;

CONTROLLED DRUG DELIVERY;

EID: 29844441008     PISSN: 03233847     EISSN: None     Source Type: Journal    
DOI: 10.1002/bimj.200510169     Document Type: Article

References (15)

1. Bauer, P., Röhmel, J., Maurer, W., and Hothorn, L. (1998). Testing strategies in multi-dose experiments including active control. Statistics in Medicine 17, 2133-2146.
2. Brown, D. J. (2003). ICH E9 Guideline 'Statistical principles for clinical trials': a case study. Response to A. Phillips and V. Haudiquet. Statistics in Medicine 22,13-17.
3. Committee for Proprietary Medicinal Products (2002). Note for guidance on the clinical investigation of medicinal products in the treatment of asthma. (CPMP/EWP/2922/01). EMEA London.
4. Committee for Medicinal Products for Human Use (2005). Guideline on the choice of non-inferiority margin. (CPMP/EWP/2158/99). EMEA London.
5. D'Agostino, R. B. and Heeren, T. C. (1991). Multiple comparisons in over-the-counter drug clinical trials with both positive and placebo controls. Statistics in Medicine 10, 1-6.
6. Dunnett, C. W. and Tamhane, A. C. (1992). Comparisons between a new drug and active and placebo controls in an efficacy clinical trial. Statistics in Medicine 11, 1057-1063.
7. Koch, G. G., Davis, S. M., and Anderson, R. L. (1998). Methodological advances and plans for improving regulatory success for confirmatory studies. Statistics in Medicine 17, 1675-1690.
8. Koch, A. and Röhmel, J. (2004). Hypothesis testing in the gold standard design for proving the efficacy of an experimental treatment relative to placebo and a reference. Journal of Biopharmaceutical Statistics 14, 315-325.
9. Lewis, J. A., Jonsson, B., Kreutz, G., Sampaio, C., and van Zwieten-Boot, B. (2002). Placebo-controlled trials and the Declaration of Helsinki. The Lancet 359, 1337-1340.
10. Ng, T.-H. (1993). A specification of treatment differences in the design of clinical trials with active controls. Drug Information Journal 27, 705-719.
11. Ng, T.-H. (2001). Choice of delta in equivalence testing. Drug Information Journal 35, 1517-1527.
12. Pigeot, I., Schäfer, J., Röhmel, J., and Hauschke, D. (2003). Assessing the therapeutic equivalence of two treatments in comparison with a placebo group. Statistics in Medicine 22, 883-899.
13. Röhmel, J. (1998). Therapeutic equivalence investigations: statistical considerations. Statistics in Medicine 17, 1703-1714.
14. Temple, R. and Ellenberg, S. S. (2000). Placebo-controlled trials and active-control trials in the evaluation of new treatments. Annals of Internal Medicine 133, 464-470.
15. World Medical Association. Declaration of Helsinki (revised 2002). www.wma.net/e/policy/17-c_e.html.